# Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy

> **NCT06224790** · PHASE4 · COMPLETED · sponsor: **Sidrah Lodhi** · enrollment: 60 (actual)

## Conditions studied

- Diabetic Nephropathies
- Type 2 Diabetes

## Interventions

- **DRUG:** Pirfenidone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06224790
- **Lead sponsor:** Sidrah Lodhi
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-10
- **Primary completion:** 2025-03-07
- **Final completion:** 2025-03-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06224790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06224790, "Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06224790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*